4.3 Article

Genetic Determinants of Lipids and Cardiovascular Disease Outcomes A Wide-Angled Mendelian Randomization Investigation

期刊

CIRCULATION-GENOMIC AND PRECISION MEDICINE
卷 12, 期 12, 页码 543-551

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCGEN.119.002711

关键词

aortic valve stenosis; epidemiology; lipids; Mendelian randomization; venous thromboembolism

资金

  1. UK Medical Research Council [G0800270, MR/L003120/1, MC_UU_12013/3]
  2. British Heart Foundation [SP/09/002, RG/08/014, RG13/13/30194]
  3. National Institute for Health Research (NIHR) through the Cambridge Biomedical Research Centre [HEALTHF2-2012-279233]
  4. European Commission
  5. NIHR Blood and Transplant Research Unit (BTRU) [NIHR BTRU-2014-10024]
  6. Wellcome Trust
  7. Royal Society [204623/Z/16/Z]
  8. NIHR BTRU PhD Studentship - Wellcome 4i Clinical PhD Programme at Imperial College London
  9. UKRI Innovation Fellowship [MR/S004068/1]
  10. EU/EFPIA Innovative Medicines Initiative
  11. Cambridge Substantive Site of Health Data Research UK [116074]
  12. National Institute for Health Research (Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust)
  13. MRC [MC_UU_00002/7, MR/S004068/1, G0800270, MR/S004068/2, MR/L003120/1] Funding Source: UKRI

向作者/读者索取更多资源

BACKGROUND: Evidence from randomized trials has shown that therapies that lower LDL (low-density lipoprotein)-cholesterol and triglycerides reduce coronary artery disease (CAD) risk. However, there is still uncertainty about their effects on other cardiovascular outcomes. We therefore performed a systematic investigation of causal relationships between circulating lipids and cardiovascular outcomes using a Mendelian randomization approach. METHODS: In the primary analysis, we performed 2-sample multivariable Mendelian randomization using data from participants of European ancestry. We also conducted univariable analyses using inverse-variance weighted and robust methods, and gene-specific analyses using variants that can be considered as proxies for specific lipid-lowering medications. We obtained associations with lipid fractions from the Global Lipids Genetics Consortium, a meta-analysis of 188 577 participants, and genetic associations with cardiovascular outcomes from 367 703 participants in UK Biobank. RESULTS: For LDL-cholesterol, in addition to the expected positive associations with CAD risk (odds ratio [OR] per 1 SD increase, 1.45 [95% CI, 1.35-1.57]) and other atheromatous outcomes (ischemic cerebrovascular disease and peripheral vascular disease), we found independent associations of genetically predicted LDL-cholesterol with abdominal aortic aneurysm (OR, 1.75 [95% Cl, 1.40-2.17]) and aortic valve stenosis (OR, 1.46 [95% CI, 1.25-1.70]). Genetically predicted triglyceride levels were positively associated with CAD (OR, 1.25 [95% CI, 1.12-1.40]), aortic valve stenosis (OR, 1.29 [95% CI, 1.04-1.61]), and hypertension (OR, 1.17 [95% CI, 1.07-1.27]), but inversely associated with venous thromboembolism (OR, 0.79 [95% CI, 0.67-0.93]) and hemorrhagic stroke (OR, 0.78 [95% CI, 0.62-0.98]). We also found positive associations of genetically predicted LDL-cholesterol and triglycerides with heart failure that appeared to be mediated by CAD. CONCLUSIONS: Lowering LDL-cholesterol is likely to prevent abdominal aortic aneurysm and aortic stenosis, in addition to CAD and other atheromatous cardiovascular outcomes. Lowering triglycerides is likely to prevent CAD and aortic valve stenosis but may increase thromboembolic risk.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据